Sun Pharma to market its own version of Vortioxetine, signs agreement with Lundbeck
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder in adults.
Mumbai: Sun Pharmaceutical Industries Limited today announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIF. The territory of the licensing agreement will only cover India.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada, and Australia.
MDD is one of the leading causes of disability, affecting approximately 246 million people globally and 35 million people in India. MDD is characterized by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behavior.
Read Also - Sun Pharma arm presents phase 3 data for acne vulgaris cream WINLEVI at AAD meeting
Sun Pharma is ranked No. 1 by prescriptions and value amongst Neurologists & Psychiatrists in India. With a strong product portfolio, Sun Pharma's CNS division constantly strives to provide innovative solutions to patients and health care providers in India.
H. Lundbeck is a global pharmaceutical company specializing in brain diseases.
Read Also - Sun Pharma gets CDSCO panel nod to conduct phase 4 study of Cyclosporine Ophthalmic Solution
